132 related articles for article (PubMed ID: 16827118)
1. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.
Fryar-Tita EB; Das JR; Davis JH; Desoto JA; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(3B):1393-9. PubMed ID: 17595753
[TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
[TBL] [Abstract][Full Text] [Related]
5. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.
De Soto JA; Bowen D; Davis JH; Southerland WM; Hawkins M
Anticancer Res; 2002; 22(2A):1007-9. PubMed ID: 12014617
[TBL] [Abstract][Full Text] [Related]
6. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
7. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
Das JR; Fryar EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
[TBL] [Abstract][Full Text] [Related]
8. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
[TBL] [Abstract][Full Text] [Related]
9. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
[TBL] [Abstract][Full Text] [Related]
10. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(2A):985-8. PubMed ID: 10368642
[TBL] [Abstract][Full Text] [Related]
12. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells.
Bowen D; Southerland WM; Hawkins M; Johnson DH
Anticancer Res; 2000; 20(3A):1415-7. PubMed ID: 10928050
[TBL] [Abstract][Full Text] [Related]
13. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
Bowen D; Johnson DH; Southerland WM; Hughes DE; Hawkins M
Anticancer Res; 1999; 19(5B):3837-40. PubMed ID: 10628320
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
[TBL] [Abstract][Full Text] [Related]
15. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
[TBL] [Abstract][Full Text] [Related]
16. Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2007; 12(1):71-6. PubMed ID: 17436405
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
18. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
Benz C; Tillis T; Tattelman E; Cadman E
Cancer Res; 1982 May; 42(5):2081-6. PubMed ID: 6175406
[TBL] [Abstract][Full Text] [Related]
19. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent.
Kanaan YM; Das JR; Bakare O; Enwerem NM; Berhe S; Beyene D; Williams V; Zhou Y; Copeland RL
Anticancer Res; 2009 Jan; 29(1):191-9. PubMed ID: 19331150
[TBL] [Abstract][Full Text] [Related]
20. [Sequential methotrexate and 5-fluorouracil].
Sasaki T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1907-10. PubMed ID: 8978795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
